Mipletamig Triplet Produces Early Responses in TP53-Mutated Frontline AML

Company: Aptevo Therapeutics · Drug: Mipletamig + Venetoclax + Azacitidine · Trial: RAINIER (Phase Ib/II) · Indication: TP53-Mutated Frontline AML · Date: September 3, 2026 Summary Aptevo reported that 13 of 14 evaluable, newly diagnosed patients with TP53-mutated acute myeloid leukemia derived a protocol-defined clinical…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Tags
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *

Saturday Rounds

Genentech / Astex | Breast Cancer Discovery Collaboration Amid gRED Restructuring
Sobi Licenses Lacutamab in $580 Million Deal
Neomorph – $100M Molecular Glue Financing
Dyne Seeks $300 Million After BLA Acceptance